
**PROFIT GUIDANCE FOR UNAUDITED FINANCIAL RESULTS
FOR FIRST QUARTER ENDED 31 MARCH 2016**

The Board of Directors (the “**Board**”) of Pharmesis International Ltd. (the “**Company**”) wishes to announce that after preliminary assessment of the Company’s unaudited financial results for the first quarter ended 31 March 2016 (“**1Q2016**”), the Board would like to inform the shareholders and investors that the Company is expected to report a net loss for unaudited financial results for 1Q2016.

The expected net loss was mainly attributed to lower revenue from prescribed drugs segment and absence of interest income from structured deposit.

Further details of the Company’s financial performance will be disclosed when the Company announces its unaudited financial results for 1Q2016 on 9 May 2016.

The Board wishes to advise its shareholders and investors to exercise caution when dealing with the shares of the Company. Shareholders and investors should consult with their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

BY ORDER OF THE BOARD

Jiang Yun
Executive Chairman
3 May 2016